New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
07:42 EDTBGMDBG Medicine outlines new commercial strategy, reorganizes R&D unit
BG Medicine provided an update on its new commercial strategy to speed the adoption of its cardiovascular diagnostic tests the BGM Galectin-3 test and the CardioSCORETM test. Under the plan announced, BG Medicine has begun to build its own dedicated sales organization and has taken steps to open its own CLIA lab in order to play a more active role alongside its commercial partners in driving sales and marketing efforts. In addition, the company highlighted its new Galectin-3 promotion effort, and provided an update on the regulatory and commercial path forward for CardioSCORE. Highlights of the new commercial strategy include: The launch of a major campaign to grow BGM Galectin-3 test sales in hospital settings. The conversion of a medical liaison organization to a US-based sales organization. The opening of a CLIA, or Clinical Laboratory Improvement Amendments, certified clinical laboratory. And a commercial strategy for CardioSCORE. In addition, the company announced a strategic reorganization in its research and development department, away from its previous focus on early stage discovery and toward a more commercially-oriented role in support of the BGM Galectin-3 and CardioSCORE tests in the marketplace. As a result of this reorganization, 11 positions in early discovery research have been eliminated, enabling the company to dedicate a greater share of its R&D budget to commercial support and market growth activities.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BGMD

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use